(+)-Hydrastine, a Potent Competitive Antagonist at Mammalian GABAA Receptors

Total Page:16

File Type:pdf, Size:1020Kb

(+)-Hydrastine, a Potent Competitive Antagonist at Mammalian GABAA Receptors ,'-. 27-30© Pes Lt, 99 Macmillan Press Ltd, 1990 Br. Br.J.Phamaol.(190,J. Pharmacol. (1990), ", 727-730 (+)-Hydrastine, a potent competitive antagonist at mammalian GABAA receptors 'Jun-Hua Huang & 2Graham A.R. Johnston Department of Pharmacology, The University of Sydney, NSW, 2006, Australia 1 (+)-Hydrastine is a phthalide isoquinoline alkaloid, isolated from Corydalis stricta. It has the same 1S,9R configuration as the competitive GABAA receptor antagonist bicuculline and is the enantiomer of the commercially available (- )hydrastine. 2 (+)-Hydrastine (CD50 0.16mgkg-', i.v.) was twice as potent as bicuculline (CD50 0.32mgkg 1, i.v.) as a convulsant in mice. This action was stereoselective in that (+)-hydrastine was 180 times as potent as (-)-hydrastine. 3 (+)-Hydrastine was a selective antagonist at bicuculline-sensitive GABAA receptors in the guinea-pig isolated ileum. It did not influence phaclofen-sensitive GABAB receptors or acetylcholine receptors in this tissue. (+)-Hydrastine was a competitive antagonist of GABAA responses (pA2 6.5) more potent than bicuculline (pA2 6.1). 4 When tested against the binding of [3H]-muscimol to high affinity GABAA binding sites in rat brain membranes, (+)-hydrastine (IC50 2.37 yM) was 8 times more potent than bicuculline (IC5o 19.7 pM). 5 As an antagonist of the activation of low affinity GABAA receptors as measured by the stimulation by GABA of [3H]-diazepam binding to rat brain membranes, (+)-hydrastine (IC5o 0.4 gM) was more potent than bicuculline (IC50 2.3 pM). 6 (+)-Hydrastine, 10 nm to 1 mM, did not inhibit the binding of [3H]-(-)-baclofen to GABAB binding sites in rat brain membranes. Introduction Methods The discovery of bicuculline as an antagonist of certain inhibi- Convulsant potencies tory actions of 4-aminobutanoic acid (GABA) on central neu- rones provided vital pharmacological evidence for the role of Convulsant potencies were assessed on injection of aqueous neurotransmitter in the CNS (Curtis solutions of the alkaloids as hydrochlorides into the tail veins GABA as an inhibitory value et al., 1970). Mammalian GABA receptors are currently classi- of male mice weighing between 18 and 25g. The CD50 fied into at least two pharmacological classes: GABAA recep- was defined as the dose causing convulsive seizures in 50% of tors are antagonized by bicuculline and insensitive to mice within 1 min of injection. baclofen, whereas GABAB receptors are activated by baclofen, antagonized by phaclofen and insensitive to bicuculline (Hill Bowery, 1981; Johnston, 1986; Kerr et al., 1987). & 0 2N CH30 Bicuculline is a phthalide isoquinoline alkaloid first isolated 4 and subsequently from Dicentra cucullaria (Manske, 1932) 0 CH30 111CH3 from a variety of species of Corydalis, Dicentra and Adlumia HHHCH H H was (Kametani, 1969). Its convulsant action reported by 3. io0 Welch & Henderson (1934). Many isoquinoline alkaloids 6'3 produce convulsions on systemic administration to mammals, antagonism appears to be restricted to the phtha- 120 0 but GABA 0 0olmn (S R lide isoquinoline alkaloids that have the lS,9R configuration, i.e. bicuculline and corlumine (Figure 1, Curtis & Johnston, 1974). Thus (-)-bicuculline (1R,9S), (-)-hydrastine (1R,9S), Bicuculline (iS, 9R) Corlumine (iS, 9R) (-)-adlumine (lR,9R) and (+)-adlumine (lS,9S) are inactive as GABA antagonists (Curtis & Johnston, 1974). Bicuculline is more potent than the closely structurally 0 " related corlumine (Figure 1) as a convulsant and as a selective GABA antagonist (Rice, 1938; Johnston et al., 1972). The H H present study concerns (+)-hydrastine, a 1S,9R, configured 0 phthalide isoquinoline alkaloid structurally related to bicuculline and corlumine, which has been isolated from 0 Corydalis stricta (Fang et al., 1981) and is the enantiomer of CH30 ICH3 the commercially available (-)-hydrastine (Figure 1). (+)- CH30 OCH3 be more potent than bicuculline in 4 Hydrastine appears to (1R, 9S) test systems using 3 animal species. (+)-Hydrastine (1S, 9R) (-)-Hydrastine Figure 1 Structures of the phthalide isoquinoline alkaloids and showing 1 On leave from Department of Pharmacology, Institute of Materia bicuculline, corlumine, (+)-hydrastine (-)-hydrastine, China. the numbering system and indicating the absolute configurations Medica, Chinese Academy of Medical Sciences, 100050 Beijing, 1 2 Author for correspondence. about carbons and 9. 728 J.-H. HUANG & G.A.R. JOHNSTON Guinea-pig isolated ileum preparation a competitive antagonist for its receptor) were calculated from Clark plots (see Krantis & Kerr, 1981) and CD5o values (dose Guinea-pigs of either sex, weighing between 200-400g, were producing convulsions in 50% of animals) from log-probit stunned by a blow on the head, segments of the distal ileum analyses as described by Tallarida & Murray (1981). Values 3-4cm in length were quickly removed, emptied of their con- are expressed as means + standard error (s.e.). tents and mounted vertically in a 20 ml organ bath containing modified Krebs solution of following composition (mM): Na' 151.0, K+ 4.6, Mg2+ 0.6, Ca2+ 2.8, Cl- 134.9, HCO- 24.9, Results H2PO4 1.3, S02- 0.6, glucose 7.7 (pH 7.4 at 370C). The Krebs solution was continuously gassed with a mixture of 95% 02 and 5% CO2. The tissues were initially placed under a resting Convulsant potencies tension of 1 g and were allowed to equilibrate for 60 min in the bath. Isometric contractions of the longitudinal muscle were Bicuculline and (+)-hydrastine produced similar convulsions measured with a Grass FT03 force transducer and recorded in mice on intravenous injection. (+}Hydrastine was more on a Grass polygraph. Antagonists were added at least 2min potent than bicuculline on the basis of relative CD5o values: before agonists were tested at 8-15min intervals, depending 0.16 + 0.01mgkg-' and 0.32 + 0.01mgkg-1 respectively on the recovery of the tissue responses to base line level. (means + s.e., n = 10). The action of (+)-hydrastine was Added drug volumes never exceeded 2% of the bath volume stereoselective in that (-)-hydrastine was some 180 times less (Krantis & Kerr, 1981; Ong et al., 1988). potent (CD50 29.8 mg kg- 1) than (+ )-hydrastine. Ligand binding studies [3H]-muscimol, [3H]-diazepam, and [3H]-(-)-baclofen Guinea-pig ileal responses to GABA and acetylcholine Whole rat brain was homogenized in 1:10 (w/v) volumes of When GABA was applied to the guinea-pig isolated ileum, cold 0.32 M sucrose. The homogenate was centrifuged at it produced either contractions or biphasic responses 1000g for 10min. The sucrose supernatant was centrifuged at (transient contractions followed immediately by relaxation). 12,000 g for 20 min to yield a crude mitochondrial pellet which The GABA-induced contractions, which are known to be was subsequently processed in different ways for the different mediated by bicuculline-sensitive GABAA receptors, were ligand binding assays. antagonized in a dose-dependent manner by (+)-hydrastine, [3H]-diazepam binding was studied by a filtration assay which had no effect upon tissue activity when added to the essentially as described by Skerritt et al. (1982a): the well- bath alone. (+)-Hydrastine at doses of 1 and 5juM elicited a washed crude mitochondrial pellet was incubated for 20min parallel shift to the right in the dose-response curve for at 4°C in 1 ml containing 530 ug membrane protein, 50mM GABA-induced contractions (Figure 2). Clark analysis indi- Tris HCl buffer, 560pM [3H]-diazepam and test compounds. cated the pA2 value for (+)-hydrastine was 6.5 + 0.2 (0.31 gM) Nonspecific binding was determined by the addition of 100pM while the pA2 value for bicuculline was 6.12 + 0.14 (0.75 jM) unlabelled diazepam. (Krantis & Kerr, 1981). The pA2values showed that (+)- [3H]-muscimol binding was studied in a similar manner hydrastine is 2.4 times stronger than bicuculline in inhibiting using membranes extracted with 0.05% Triton X-100 Tris GABA-induced contractile responses in guinea-pig ileum. citrate buffer at 37°C for 30min. After thorough washing the (+)-Hydrastine at 1 gM did not show any effect on Triton treated membranes were incubated for 60 min at 4°C in acetylcholine-induced contractile responses in guinea-pig a volume of 1 ml containing 690 jg membrane protein, 50mM ileum or on relaxations mediated by GABAB receptors. Tris HCl buffer (pH 7.4), 1.47 nm [3H]-muscimol and test compounds. Nonspecific binding was determined by the addi- tion of 100 M unlabelled GABA. Muscimol binding to high affinity GABAA binding sites [3H]-(-)-baclofen binding was studied in a centrifugation on rat brain membranes assay as described by Drew et al. (1984). Protein for all of the receptor binding assays was measured Equilibrium binding assays revealed that (+)-hydrastine and by the method of Lowry et al. (1951). bicuculline inhibited [3H]-muscimol binding to rat brain membranes, whereas (-)-hydrastine was inactive (Figure 3). Materials The following IC50 values were determined by computer analyses: (+)-hydrastine 2.37 + 0.45 gM; bicuculline 19.7 (+)-Hydrastine, isolated from Corydalis stricta, was the gift of + 5.2juM. Scatchard analysis of the results of [3H]-muscimol Professor Fang Qi-Cheng in the Institute of Materia Medica, binding studies indicated binding to a single population of Chinese Academy of Medical Sciences, Beijing. Bicuculline high affinity sites with a Kd of 2.91 + 0.86nM and a B,,, of methochloride and phaclofen were synthesized in the Depart- 1.09 + 0.18 nmol mg- ' protein. ment of Pharmacology at the University of Sydney by Ms Christine Apostopoulos and
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Thesis Rests with Its Author
    University of Bath PHD A modelling study of the ligand-gated ion-channel superfamily of receptors Cockcroft, Victor Barrie Award date: 1992 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 08. Oct. 2021 A MODELLING STUDY OF THE LIGAND-GATED ION-CHANNEL SUPERFAMILY OF RECEPTORS. submitted by Victor Barrie Cockcroft for the degree of Ph.D. at the University of Bath 1992 Copyright Attention is drawn to the fact that the copyright of this thesis rests with its author. This copy of the thesis has been supplied on the condition that anyone who con­ sults it is understood to recognize that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published with­ out the prior written consent of the author.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Assessment of Molecular Action of Direct Gating and Allosteric Modulatory Effects of Carisoprodol (Somartm) on GABA a Receptors
    Graduate Theses, Dissertations, and Problem Reports 2015 Assessment of molecular action of direct gating and allosteric modulatory effects of carisoprodol (SomaRTM) on GABA A receptors Manoj Kumar Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Kumar, Manoj, "Assessment of molecular action of direct gating and allosteric modulatory effects of carisoprodol (SomaRTM) on GABA A receptors" (2015). Graduate Theses, Dissertations, and Problem Reports. 6022. https://researchrepository.wvu.edu/etd/6022 This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. ASSESSMENT OF MOLECULAR ACTION OF DIRECT GATING AND ALLOSTERIC MODULATORY EFFECTS OF MEPROBAMATE (MILTOWN®) ON GABAA RECEPTORS Manish Kumar, MD, MS Dissertation submitted to the School of Pharmacy at West Virginia University in partial fulfillment of Requirements
    [Show full text]
  • Pharmacology
    PHARMACOLOGY STUDY GUIDE FOR THE SPECIALTY «GENERAL MEDICINE» Minsk BSMU 2018 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 3-е издание, исправленное Минск БГМУ 2018 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 20.06.2018 г., протокол № 10 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е нты: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 3-е изд., испр. – Минск : БГМУ, 2018. – 152 с. ISBN 978-985-21-0103-5. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0103-5 © УО «Белорусский государственный медицинский университет», 2018 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ...........................................................................................................................................
    [Show full text]
  • Benzodiazepines and the GABA, Receptor: Effecs of C~~UB~Cexposure
    The University of Alberta Benzodiazepines and the GABA, Receptor: Effecs of C~~UB~CExposure Michelle Ingird Arnot O A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillrnent of the requirements for the degree of Doctor of Philosophy. Department of Pharmacology Edmonton, Alberta FaIl, 1998 National Library Bibliothèque nationale of Canada du Canada Acquisitions and Acquisitions et Bibliographie Services services bibliographiques 395 Wellington Street 395, me Wellington OüawaON K1AW ûüawaON K1AON4 Canada canada The author has granted a non- L'auteur a accorde une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distn'buer ou copies of this thesis in microform, vendre des copies de cette thése sous paper or electronic formats. la forme de microfiche/nlm, de reproduction sur papier ou sur format élecîronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thése ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. A mind once stretched by a new idea, never regains its original dimensions. - Author Unknown ABSTRACT The benzodiazepine pharmacological profile includes sedation. anxiolysis. muscle relaxation and anticonvulsant effects; however. after long term treatment with full agonists tolerancc develops to certain aspects of this profile. These cornpounds produce their overt effects via allosrenc modulation of the GABA, receptor.
    [Show full text]
  • World of Cognitive Enhancers
    ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Allosteric Activation Mechanism of the A1b2 2 -Aminobutyric Acid Type A
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 2542 Biophysical Journal Volume 77 November 1999 2542–2551 Allosteric Activation Mechanism of the ␣1␤2␥2 ␥-Aminobutyric Acid Type A Receptor Revealed by Mutation of the Conserved M2 Leucine Yongchang Chang and David S. Weiss Departments of Neurobiology and Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama 35294-0021 USA ABSTRACT A conserved leucine residue in the midpoint of the second transmembrane domain (M2) of the ligand-activated ion channel family has been proposed to play an important role in receptor activation. In this study, we assessed the importance of this leucine in the activation of rat ␣1␤2␥2 GABA receptors expressed in Xenopus laevis oocytes by site-directed mutagenesis and two-electrode voltage clamp. The hydrophobic conserved M2 leucines in ␣1(L263), ␤2(L259), and ␥2(L274) subunits were mutated to the hydrophilic amino acid residue serine and coexpressed in all possible combina- tions with their wild-type and/or mutant counterparts. The mutation in any one subunit decreased the EC50 and created spontaneous openings that were blocked by picrotoxin and, surprisingly, by the competitive antagonist bicuculline. The magnitudes of the shifts in GABA EC50 and picrotoxin IC50 as well as the degree of spontaneous openings were all correlated with the number of subunits carrying the leucine mutation. Simultaneous mutation of the GABA binding site (␤2Y157S; ␤ increased the EC50) and the conserved M2 leucine ( 2L259S; decreased the EC50) produced receptors with the predicted intermediate agonist sensitivity, indicating the two mutations affect binding and gating independently.
    [Show full text]
  • Sternum. ^Sympathetic Chain \ to Prevertebral
    Durham E-Theses An electrophysiological study of the interaction between fenamate NSAIDs and the GABA(_A) receptor Patten, Debra How to cite: Patten, Debra (1999) An electrophysiological study of the interaction between fenamate NSAIDs and the GABA(_A) receptor, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/4561/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk 2 An electrophysiological study of the interaction between Fenamate NSAIDs and the GABAA receptor. Debra Patten Submitted for the Degree of Ph.D. The copyright of this thesis rests with the author. No quotation from it should be published without the written consent of the author and information derived from it should be acknowledged. 1 9 JUL 2000 Dept. of Biological Sciences University of Durham March 1999 March 1999 Table of Contents AN ELECTROPHYSIOLOGICAL STUDY OF THE INTERACTION BETWEEN FENAMATE NSAIDs AND THE GABAA RECEPTOR CHAPTER ONE: GENERAL INTRODUCTION 1.1.
    [Show full text]